Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash from Investing Activities (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Cash from Investing Activities data on record, last reported at $10.4 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 111.69% year-over-year to $10.4 million; the TTM value through Dec 2025 reached $48.4 million, up 169.32%, while the annual FY2025 figure was $48.4 million, 169.32% up from the prior year.
  • Cash from Investing Activities reached $10.4 million in Q4 2025 per ACRS's latest filing, down from $13.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $32.5 million in Q3 2023 and bottomed at -$88.7 million in Q4 2024.
  • Average Cash from Investing Activities over 5 years is -$6.5 million, with a median of $2.7 million recorded in 2022.
  • Peak YoY movement for Cash from Investing Activities: skyrocketed 2573.29% in 2023, then crashed 1275.14% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$9.2 million in 2021, then soared by 129.45% to $2.7 million in 2022, then soared by 179.42% to $7.6 million in 2023, then plummeted by 1275.14% to -$88.7 million in 2024, then skyrocketed by 111.69% to $10.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $10.4 million in Q4 2025, $13.8 million in Q3 2025, and $5.0 million in Q2 2025.